Cytokinetics Inc and Ji Xing Pharmaceuticals Ltd Call to Discuss Announced Expansion of Collaboration Transcript
Good morning, and welcome, ladies and gentlemen, to the Cytokinetics conference call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions) I will now turn the call over to Joanna Siegall, Cytokinetics' Senior Manager of Corporate Communications and Investor Relations. Please go ahead.
Good morning, everyone, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will lead us off today with an overview will lead us off today with an overview of today's announcement; then Libby Schnieders, Senior Vice President of Business Development, will speak to the specifics of the deal. Before Ching Jaw, our SVP and Chief Financial Officer, will summarize the financial terms and how they inform our financial outlook.
Next, Fady Malik, our Executive Vice President of R&D, will discuss the impact of these transactions on the future development and commercialization for omecamtiv mecarbil before Robert will provide final comments and open the call for questions. At
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |